Zyn FDA nicotine pouches tobacco smoking cancer.

The Food and Drug Administration is weighing whether to allow new advertising messages about Zyn, a type of nicotine pouch that’s growing in popularity. Agency advisers are holding an all-day meeting Thursday to consider a request from Philip Morris to begin promoting Zyn as a less-harmful alternative for adult smokers. Studies submitted by the company suggest that switching to Zyn can lower the risks of lung cancer, stroke and other smoking-related ailments. But the FDA and its advisers must weigh those benefits against other potential risks, including use by underage teenagers.